Tiam1-deficiency impairs mammary tumor formation in MMTV-c- but not in MMTV-c- mice by unknown
J Cancer Res Clin Oncol (2009) 135:69–80
DOI 10.1007/s00432-008-0437-8
ORIGINAL PAPER
Tiam1-deWciency impairs mammary tumor formation 
in MMTV-c-neu but not in MMTV-c-myc mice
K. Strumane · T. Rygiel · M. van der Valk · 
J. G. Collard 
Received: 26 May 2008 / Accepted: 9 June 2008 / Published online: 1 July 2008
©  The Author(s) 2008
Abstract
Background Rho-like small GTPases, including RhoA,
Rac1 and Cdc42, are crucial for the regulation of a large vari-
ety of biological processes such as the cytoskeletal organiza-
tion and gene transcription. The activities of Rho GTPases are
predominantly controlled by guanine nucleotide exchange
factors (GEFs), which activate GTPases by catalyzing the
exchange of bound GDP for GTP. Earlier, we have identiWed
the Tiam1 gene as an invasion-inducing gene that encodes a
speciWc activator (GEF) of the Rac GTPase. We found that
Tiam1-mediated Rac signaling functions in various aspects of
tumorigenicity including the formation and progression of
Ras-induced skin tumors and Wnt-induced intestinal tumors.
Here, we further distinguish the oncogenic pathways that
depend on Tiam1 signaling in the mammary gland.
Material and methods  We crossed Tiam1 knockout mice
with MMTV-c-myc and MMTV-c-neu transgenic mice, in
which the expression of both oncogenes is targeted to the
mammary gland leading to mammary tumorigenesis.
Results We found Tiam1 important for Neu-induced
tumor formation and progression but not for Myc-induced
tumors. Tiam1-deWciency delayed Neu-induced tumor initi-
ation and reduced metastasis but had no eVect on the
growth of the MMTV-c-neu tumors.
Conclusion  Our data indicate that the Rac activator
Tiam1 contributes to tumorigenicity induced by speciWc
oncogenic signaling pathways only.
Keywords Tiam1 · Rac · Transgenic mice · 
Mammary tumors · Neu · Myc · MMTV
Introduction
The activity of Rho-like GTPases in response to receptor
stimulation is strictly controlled to stimulate, locally and
temporally, speciWc downstream signaling pathways in
cells. The regulators of the activity of Rho GTPases consist
of three classes of proteins: guanine nucleotide exchange
factors (GEFs), GTPase-activating proteins (GAPs) and
guanine nucleotide dissociation inhibitors (GDIs). To date,
over 70 Rho GEFs have been identiWed (Schmidt and Hall
2002). In earlier studies, we have identiWed the Tiam1 gene
(T-cell invasion and metastasis gene 1), which encodes a
speciWc GEF and thus activator of the Rho-like GTPase
Rac (Habets et al. 1994; Michiels et al. 1995). Rho GTP-
ases are best characterized for their regulation of actin cyto-
skeleton dynamics, but they also control various other
processes including apoptosis, cell proliferation and gene
transcription (Bishop and Hall 2000). It is therefore not sur-
prising that Rho GTPases and their regulators may contrib-
ute to various aspects of tumorigenicity (Malliri et al.
2002a; Sahai and Marshall 2002).
The activators of Rho GTPases not only catalyze GDP/
GTP exchange but also contribute to RhoGTPase down-
stream signaling by connecting active GTPases to speciWc
scaVold and eVector proteins (Mertens et al. 2003; Ross-
man et al. 2005). ScaVold proteins that complex Tiam1
with components of speciWc Rac eVector pathways include
IB2 and spinophilin, which direct Tiam1-mediated Rac
activation towards the p38 MAPK and p70S6 K cascades
implicated in transcription and translation, respectively
(Buchsbaum et al. 2002, 2003). Tiam1 also binds to diVerent
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regulates polarity processes in various cell types. Tiam1
associates with Par3 and PKC and connects Tiam1-medi-
ated Rac signaling to the establishment of apical–basal cell
polarity in contacting epithelial cells as well as front–rear
polarity in freely migrating epithelial cells (Chen and
Macara 2005; Mertens et al. 2005; Pegtel et al. 2007).
Tiam1 also associates with activated Rap1 and in conjunc-
tion with the Par polarity complex controls chemokine-
induced T-cell polarization (Gerard et al. 2007). The asso-
ciation of Tiam1 with IRSp53 and p21Arc provides a direct
link between Tiam1-mediated Rac activation and Arp2/3
complex-controlled actin polarization, which is required for
cytoskeletal dynamics during cell migration and cell polari-
zation (Connolly et al. 2005; ten Klooster et al. 2006). In
receptor signaling, activated Ras may activate Rac by direct
binding to Tiam1 (Lambert et al. 2002) or indirectly by
activation of phosphoinositide 3-kinase (PI3-kinase) that
may recruit and activate Tiam1 and thereby Rac down-
stream of Ras (Fleming et al. 2000; Zondag et al. 2000).
Tiam1 is expressed in human and rodent tumor cells of
diVerent tissue origin and has been shown to aVect various
aspects of tumorigenicity (Habets et al. 1995; Minard et al.
2004). The inXuence of Tiam1 on diVerent stages of tumor
development is illustrated in previous studies using mouse
tumor model systems and Tiam1 knockout (Tiam1¡/¡)
mice. Tiam1-deWciency inhibits Ras-induced mouse skin
tumor initiation and growth in a two-stage DMBA/TPA
carcinogenesis model (Malliri et al. 2002b). These skin
tumors arise by DMBA-induced Ras mutations in keratino-
cytes of the epidermis. Tiam1¡/¡ mice are more resistant to
the Ras-induced skin tumor development because epider-
mal keratinocytes are more susceptible for Ras-induced
apoptosis during tumor initiation. Although the few Ras-
induced skin tumors that do occur in Tiam1¡/¡ mice grow
much slower than wild type tumors, they convert more fre-
quently to a malignant phenotype, presumably as a result of
the function of Tiam1 in maintenance of E-cadherin-based
cell–cell adhesions (Malliri et al. 2002b, 2004). Such a
bifunctional eVect of Tiam1-deWciency on tumor formation
and progression was also found for intestinal tumors in
APC Min (multiple intestinal neoplasia) mutant mice (Mal-
liri et al. 2006). Tiam1 is a Wnt-responsive gene in colon
cells and its deWciency reduces the formation and growth of
polyps in APC Min mutant mice but promotes invasion of
progressed malignant intestinal tumors (Malliri et al. 2006).
These in vivo data indicate that Tiam1 functions down-
stream of at least two independent oncogenic signaling
pathways, i.e., the Ras and the Wnt pathway.
Tiam1 is thus a potential therapeutic target, and chemi-
cal inhibitors have been developed to inhibit the function of
Tiam1 and Rac in tumors in vivo (Gao et al. 2004; Shutes
et al. 2007). In this context, it is important to decipher the
speciWcity of Tiam1 as a modiWer of tumor development
and progression in the context of diVerent oncogenic sig-
naling pathways and of tumor cell types. Therefore, we
investigated the function of Tiam1 in mammary tumorigen-
esis induced by two alternative oncogenic signaling path-
ways. We crossed Tiam1¡/¡ mice with two strains of breast
cancer prone transgenic mice that express oncogenic Myc
or Neu under the control of the mouse mammary tumor
virus (MMTV) promoter. Interestingly, we found that
Tiam1-deWciency did not inXuence Myc-induced tumori-
genesis but speciWcally impaired c-neu induced mammary
tumor formation in mice, illustrating that Tiam1-mediated
Rac signaling is required for only speciWc oncogenic sig-
naling pathways that lead to tumorigenesis.
Materials and methods
Mice
A congenic line of FVB/Tiam1¡/¡ mice was used, which was
generated as described earlier (Malliri et al. 2002b). Trans-
genic MMTV-c-neu, line TG.NK (Muller et al. 1988) and
MMTV-c-myc (Stewart et al. 1984) mice were purchased
from Charles River Laboratories. All transgenic mice were
on FVB background. Transgenic male mice were crossed
with Tiam1¡/¡ females. The resulting Tiam1§/MMTV-onco-
gene males were backcrossed with female Tiam1+/+ and
Tiam1¡/¡ mice. From their oVspring, Tiam1+/+/MMTV-
oncogene and Tiam1§/MMTV-oncogene males were back-
crossed to Tiam1+/+ and Tiam1¡/¡ females, respectively, to
yield the experimental groups: Tiam1+/+/MMTV-oncogene,
Tiam1§/MMTV-oncogene, Tiam1¡/¡/MMTV-oncogene.
Only females were used for subsequent analyses. MMTV-c-
neu females were kept as virgins throughout the entire obser-
vation period. MMTV-c-myc females underwent forced
breeding for two pregnancies to promote tumorigenesis.
Mice were monitored by palpation for tumors and killed
when they harbored a mammary tumor that reached a size of
10 mm. Local ethics committee for animal experiments
approved the mouse experiments according to the Dutch law
that implements the European guideline 86/609/EEG.
Histology and immunohistochemistry
H&E stainings and immunohistochemistry were performed
on 4 m paraYn-embedded tissue sections as described
(Strumane et al. 2005). Antibodies used are as follows: an
anti-DH Tiam1-speciWc rabbit polyclonal antibody (Habets
et al. 1994), polyclonal anti-Keratin 1 (Covance/Babco,
1:250), anti-Keratin 8 (troma-1; University of Iowa,
Department of Biological Sciences, Iowa City, Iowa USA;
1:400) and anti-Keratin 14 (Covance/Babco; 1:10,000).123
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Inguinal mammary fat pads were excised from euthanized
mice and stretched on a glass slide for Wxation in metha-
nol:chloroform:acidic acid (6:3:1) for at least 24 h. After
washing in 70% ethanol for 1 h, the slides were rinsed in
water and stained in carmine for 24 h. All incubations were
performed at room temperature (RT). The fat pads were
dehydrated in a graded series of alcohols and kept in methyl
salicylate to make photographic images.
Isolation mammary epithelial cells
The left and right mammary fat pads 2 and 3 were excised
from euthanized mice at 16 weeks of age. The isolated tis-
sues were washed three times in 70% ethanol and trans-
ferred to L15 medium (Gibco BRL) with 10% fetal calf
serum (FCS). The fat pads were chopped using a scalpel
and digested in a 0.3% collagenase–0.15% trypsin mix in
serum-free L15 medium at 37°C for 1 h with periodic
shaking. Cells were pelleted and washed four times with
L15 medium with serum and subsequently incubated in
DMEM containing 10% FCS, 2 mM L-glutamine (L-Gln)
and 100 U/ml penicillin/100 g/ml streptomycin (P/S) at
37°C, 5% CO2, 5% O2 to remove contaminating Wbro-
blasts. After 1 h, the epithelial cells were still Xoating in
the medium and could be easily separated from the Wbro-
blasts that had attached to the bottom of the culture Xasks.
The pelleted epithelial cells were resuspended and cul-
tured for maximal 3 days in DMEM:F12 (1:1; Gibco-
BRL) medium containing 10% FCS and P/S and supple-
mented with 5 g/ml insulin, 5 ng/ml choleratoxin and
5 ng/ml EGF.
Western blotting
Lysates were prepared using standard SDS or RIPA lysis
buVers as indicated. Cultured cells were washed with
PBS and scraped in lysis buVer. Snap frozen tumor mate-
rial was Wrst grinded in a mortar and than lysed. Proteins
were separated by SDS-PAGE and transferred to Immo-
bilon-P membrane (Millipore). After blocking with 5%
skimmed milk, the blots are probed using the indicated
antibodies. Primary antibodies used were anti-DH
[(Habets et al. 1994);1/500] and C-16 (sc-872, Santa
Cruz, Venendaal, The Netherlands; 1/1.000) against
Tiam1, anti--tubulin (Clone B-5-1-2, Sigma, 1/5.000),
anti-c-erbB2/HER-2/neu (Ab-17, Neomarkers, 1/2.000)
and anti-Rac1 (clone 23A8, Upstate Biotechnology,
Venendaal, The Netherlands; 1/1.000). As secondary
antibodies, peroxidase-conjugated IgGs were used fol-
lowed by enhanced chemiluminiscence (ECL) detection
(Amersham).
Apoptosis quantiWcation
MDA-MB-361 cells were cultured in DMEM:F12 (1:1;
Gibco-BRL) medium supplemented with P/S, 10% FCS,
10 ng/ml EGF and 10 g/ml insulin. The Tiam1-speciWc
siRNA oligo GCGAAGGAGCAGGTTTTCT (Malliri
et al. 2004) was transfected into the MDA-MB-361 cells
using the Dharmafect-1 reagent (Dharmacon). A scram-
bled sequence was used as nonspeciWc control siRNA
oligo (siCONTROL nontargeting siRNA, Dharmacon). Six
hours after transfection, the transfection mix was replaced
by culture medium, which was refreshed again 24 h after
transfection and apoptosis was quantiWed 72 h after trans-
fection. Both Xoating and adherent cells were lysed
together and apoptosis was analyzed using the Cell Death
Detection ELISA kit (Roche) according to manufactures
instructions.
Results
Tiam1 expression in the mammary gland is increased 
in tumor tissue
We started our analyses by determining Tiam1 expression
in the mammary glands and mammary tumors of trans-
genic and nontransgenic female mice. Tiam1 is expressed
in the normal mammary gland as shown by Western blot
analysis of primary cells isolated from 16-week-old wild
type mice (Fig. 1a, left lane). At this age, we found
increased Tiam1 expression levels in the precancerous
mammary gland of MMTV-c-neu transgenic mice (Fig. 1a,
right lane). Western blot analysis revealed Tiam1 expres-
sion in both MMTV-c-myc and MMTV-c-neu tumors
(Fig. 1b). Consistent with these data, others also found that
Tiam1 was increased in MMTV-c-neu tumors compared to
normal tissue at the mRNA level (Landis et al. 2005).
Tiam1 expression in tumors was conWrmed by immunohis-
tochemical staining of mammary tumors isolated from
Tiam1+/+ mice (Fig. 1c). These data demonstrate that
Tiam1 is expressed in the mammary gland and that its
expression is increased in Neu-induced and Myc-induced
mammary tumors.
Normal mammary gland development in Tiam1-deWcient 
mice
Tiam1 knockout mice are viable and do not show any obvi-
ous aberrant phenotype (Malliri et al. 2002b). Also the
mammary glands of Tiam1¡/¡ mice are functionally normal
as Tiam1¡/¡ females are able to suckle their oVspring. To
exclude that tumorigenesis is inXuenced by morphological
diVerences in mammary gland development, we compared123
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virgin Tiam1¡/¡ female mice with that of Tiam1+/+ mice in
nontransgenic and transgenic animals at diVerent ages
(Fig. 2). The appearance of Tiam1¡/¡ mammary glands was
identical to that of wild type glands in adult mice (not
shown). However, we found a delay in the early develop-
ment of the mammary gland in Tiam1¡/¡ when compared
to wild type mice. The outgrowth of the inguinal mammary
glands is determined by how far the glands extend beyond
the inguinal lymph node (to the right side in Fig. 2). The
mammary ductal system was signiWcantly less far prolifer-
ated within the adipose stroma in 4-week-old and 6-week-
old Tiam1¡/¡ mice when compared to age-matched wild
type mice (Fig. 2 left panel). At 8 weeks, the appearance of
the mammary gland in Tiam1+/+ and Tiam1¡/¡ mice was
indistinguishable, indicating that development was delayed
but not impaired (Fig. 2 left panel). This delay in early
mammary gland elongation during puberty in Tiam1¡/¡
mice was also observed for both transgenic strains in a
Tiam1¡/¡ background as exempliWed in 6-week-old mice
(Fig. 2 right panel). By analyzing mammary glands at
diVerent time points, we found that the delay in outgrowth
of the mammary gland was most apparent at 4 weeks of
age, declined within the subsequent weeks and by 8 weeks
of age we could not discriminate anymore between wild
type and Tiam1 knockout mammary glands. As the Wrst
tumors in MMTV-oncogene mice became detectable only
by 17 weeks of age, we conclude that it is unlikely that the
delay in early normal mammary gland development aVects
mammary tumorigenesis in the mouse mammary tumor
models used.
Tiam1 is involved in mammary tumorigenesis induced 
by Neu and not by Myc
To address whether Tiam1 is involved in speciWc onco-
genic pathways, we examined mammary tumorigenesis in
MMTV-c-neu and MMTV-c-myc female mice in Tiam1+/+
and Tiam1¡/¡ backgrounds. Weekly palpation of the mice
revealed that Tiam1-deWciency strongly delayed the
appearance of tumors in MMTV-c-neu transgenic mice,
whereas the latency of mammary tumors induced by Myc
was not aVected by the loss of Tiam1 (Fig. 3). MMTV-c-
myc mice developed mammary tumors with the same
latency in Tiam1+/+ and Tiam1¡/¡ mice (Fig. 3a). Although
all except one of the MMTV-c-neu mice developed palpa-
ble tumors over an observation period of 1 year (Table 1),
the latency was signiWcantly longer in the Tiam1-deWcient
mice (P < 0.001) (Fig. 3b). At the time when tumors were
detected in 100% of the MMTV-c-neu;Tiam1+/+ mice (age
29 weeks), detectable tumors were found in only 19% of
the MMTV-c-neu;Tiam1¡/¡ mice. This delay in the rate of
tumor initiation is also reXected in the T50 that denotes the
age at which 50% of the populations possess at least one
palpable tumor. The T50 was 23.5 weeks for MMTV-c-
neu;Tiam1+/+ mice and 32.5 weeks for MMTV-c-
neu;Tiam1¡/¡ mice. Together, these data indicate that,
while Tiam1 is not required for the induction of mammary
tumors by Myc, it does play a critical role in the initiation
of mammary tumors induced by Neu. More speciWcally,
Tiam1-deWciency extends the latency of Neu-induced
mammary tumor initiation.
Tiam1-deWciency does not inXuence the type of tumor 
diVerentiation in MMTV-c-neu and MMTV-c-myc mice
We analyzed a possible relation between the involvement
of Tiam1 and the tumor characteristics. The MMTV-c-myc
and c-neu tumors were deWned as adenocarcinomas based
on histopathological analysis of hematoxylin and eosin
(H&E) stainings (Fig. 4a). To further analyze the diVerenti-
ation status of the tumors in our analysis, we performed
additional stainings for Keratins. The MMTV-c-myc and
Fig. 1 Tiam1 expression in mouse mammary tissue and tumors. a
Tiam1 is detected (C16 antibody) by Western blotting in primary epi-
thelial cells isolated from precancerous mammary glands of 16-week-
old mice. Tiam1 expression is increased in the mammary gland of
MMTV-c-neu mice compared to wild type mice. The same blot was
probed for the detection of -tubulin for loading control. b Western
blot analysis of Tiam1 protein levels in tumor samples derived from
MMTV-c-myc and MMTV-c-neu mice (C16 antibody). Two SDS ly-
sates of snap-frozen tumors isolated from diVerent mice are shown for
each transgenic line. The same blot was probed with a Rac antibody
and used as a loading control. c Expression of Tiam1 in histological tu-
mor slides. Mammary carcinomas from MMTV-c-myc;Tiam1+/+ and
MMTV-c-neu;Tiam1+/+ are shown probed for Tiam1 (anti-DH anti-






















J Cancer Res Clin Oncol (2009) 135:69–80 73c-Neu tumors were all positive for Keratin 8 in both Tiam1+/+
and Tiam1¡/¡ mice (Fig. 4b, A–D), indicating that they all
had a glandular character, although this was less evidently
suggested by the H&E staining in the case of the MMTV-c-
neu tumors. Keratin 1 is normally not expressed in the
mammary gland and is used as a marker for epidermal
diVerentiation in mammary tumors. All tumors were nega-
tive for Keratin 1 (Fig. 4b, E–H), while the adjacent skin
tissue served as an intrinsic positive control (not shown).
Although the Keratin 1 staining suggested that none of the
tumors contained epidermal characteristics, MMTV-c-myc
tumors showed a positive Keratin 14 staining indicating
squamous metaplasia (Fig. 4b, I, J) in both Tiam1+/+ and
Tiam1¡/¡ mice. However, the MMTV-c-neu tumors were
completely negative for Keratin 14 (Fig. 4b, K, L). From
these immunohistological analyses, we conclude that the
presence or lack of Tiam1 has no eVect on the diVerentia-
tion type of the MMTV-c-myc and MMTV-c-neu mam-
mary tumors. The MMTV-c-neu tumors show
homogeneously a glandular diVerentiation (Keratin 8-posi-
tive), whereas MMTV-c-myc tumors consist of diVerent
components with glandular (Keratin 8-positive) and squa-
mous (Keratin 14 positive) diVerentiation. This is in agree-
ment with the notion that MMTV-c-neu mice uniformly
develop mammary tumors (Bargmann et al. 1986; Muller
et al. 1988), whereas MMTV-c-myc mice develop mam-
mary tumors in a stochastic fashion. As reported earlier, c-
myc is necessary but not suYcient for tumorigenesis, indi-
cating that additional events are required for mammary
tumor development in these mice (Li et al. 2000; Stewart
et al. 1984; Tsukamoto et al. 1988). Taken together,
MMTV-c-neu tumors can be discriminated from MMTV-c-
myc tumors by the fact that they show glandular diVerentia-
tion only and no squamous characteristics. Furthermore, the
presence or absence of Tiam1 does not inXuence the histo-
logical type of tumors raised by Myc or Neu expression.
Tiam1-deWciency aVects initiation but not growth 
of neu-induced mammary tumors
Western blot analysis of mammary tumors in Tiam1+/+ and
Tiam1¡/¡ mice showed that disruption of Tiam1 expression
did not alter the expression levels of the Neu protein
(Fig. 5a). This excludes the possibility that the delay in
initiation of Neu-induced mammary tumors in Tiam1¡/¡
mice was caused by an inadequate expression of the neu
Fig. 2 Analysis of mammary gland development. Inguinal mammary
glands from 4-, 6-, and 8-week-old Tiam1+/+ and Tiam1¡/¡ virgin fe-
male mice were compared within the nontransgenic mice (left panel)
and from 6-week-old Tiam1+/+ and Tiam1¡/¡ mice in the MMTV-c-
myc and MMTV-c-neu transgenics (right panel). All mammary glands
are positioned in the same orientation so that the outgrowth of the
mammary glands is presented from left to right. The distance towards
or beyond the inguinal lymph node is a measure for the outgrowth of
the mammary gland. Representative images show the delay in elonga-
tion of the system of mammary ducts in the Tiam1¡/¡ mice compared
to Tiam1+/+ mice in the diVerent strains. Mammary whole mounts were
stained with carmine red. The scale bar indicates 1.5 mm
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latency of MMTV-c-neu-induced tumors in the Tiam1§
group was intermediate between that in the Tiam1+/+ and
Tiam1¡/¡ groups (Fig. 5b) suggesting a dose-dependent
eVect of Tiam1 on the initiation of Neu-induced mammary
tumors. We found earlier a similar dose-dependent eVect of
Tiam1 on Ras-induced skin tumors (Malliri et al. 2002b).
The decreased susceptibility to Neu-induced tumors in
Tiam1-deWcient mice was also reXected by a decreased
number of tumors per mouse (Fig. 5c). Mice were eutha-
nized for dissection when they harbored at least one mam-
mary tumor that reached a size of 10 mm. The median
number of tumors with a size >4 mm per mouse is four in
Tiam1+/+ mice, three tumors per mouse in Tiam1§ and two
tumors per mouse in Tiam1¡/¡ mice, again suggesting a
dose-dependent eVect of Tiam1 on tumor initiation
(Fig. 5c). Tumor growth was determined by the time
between detection of the Wrst palpable tumor and necropsy,
i.e., when the tumor had grown out to a size that reached
10 mm. We found that the average growth of individual
MMTV-c-neu tumors was not signiWcantly diVerent in
Tiam1+/+ and Tiam1¡/¡ backgrounds (Fig. 5d). This indi-
cates that once a tumor is initiated in the Tiam1¡/¡ mice, it
is able to grow as fast as in the Tiam1+/+ mice. Tiam1-deW-
ciency also did not aVect mammary tumor growth in the
MMTV-c-myc model in which tumor initiation was not
aVected (not shown). Together, these data indicate that the
delayed latency and the fewer tumors in Tiam1¡/¡ mice
compared to Tiam1+/+ mice are a consequence of a speciWc
function of Tiam1 in Neu-induced tumor initiation rather
than an involvement of Tiam1 in the growth of the mam-
mary tumors.
Tiam1 provides survival signaling in Neu-induced 
mammary tumor cells
Prevention of apoptosis is a necessary step during the pro-
cess of tumor initiation. The increased susceptibility for
apoptosis was found to be the underlying mechanism of
decreased skin tumor incidence in Tiam1¡/¡ mice (Malliri
et al. 2002b). As in Ras-induced skin tumors, it is possible
that Tiam1-deWciency results in a reduced number of
tumors in the MMTV-c-neu mouse model by increasing the
susceptibility to apoptosis of the targeted mammary epithe-
lial cells. Attempts to analyze apoptosis in vivo in estab-
lished tumors did not discriminate Neu-induced tumors
between Tiam1+/+ and Tiam1¡/¡ mice. Therefore, we ana-
lyzed the dependency of the survival of Neu-expressing
breast cancer cells on Tiam1 in vitro. As a model, we used
the human breast cancer cells MDA-MB-361, which are
characterized by high Neu expression. Western blot analy-
sis showed that MDA-MB-361 cells express Tiam1 that can
be downregulated by Tiam1-speciWc siRNA (Fig. 6a). The
susceptibility to apoptosis was measured using a cell death
detection kit that quantitatively determines cytoplasmic his-
tone-associated DNA fragments by ELISA (enzyme-linked
immunosorbent assay). Interestingly, the number of apop-
totic cells is increased upon downregulation of Tiam1 when
compared to cells that were transfected with a nonspeciWc
control siRNA (Fig. 6b), indicating that Tiam1 also con-
trols apoptosis in Neu-expressing tumor cells.
Fig. 3 Kinetics of oncogene-induced mammary tumor initiation in
Tiam1+/+ and Tiam1¡/¡ mice. The age when a palpable mammary tu-
mor Wrst appears represents the latency of tumor initiation. a Tumor
initiation in MMTV-myc;Tiam1¡/¡ (n = 20) compared to MMTV-
myc;Tiam1+/+ (n = 29) is not diVerent (P = 0.41, Student’s t test). b The
longer latency in MMTV-neu;Tiam1¡/¡ (n = 21) compared to MMTV-
neu;Tiam1+/+ (n = 26) is statistically signiWcant (P < 0.001, Student’s t



















































Table 1 Incidence of mammary tumors in transgenic mice
The presented numbers are the ratios of females displaying mammary
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of Neu-induced mammary tumors
We also analyzed the MMTV-c-neu tumor-bearing mice
for the presence of metastases by histopathological analy-
sis. We found metastases mainly in the lungs and occasion-
ally in the heart. This is consistent with earlier observations
that MMTV-c-neu-induced mammary tumors metastasize
to the lung with high frequency (Guy et al. 1992; Siegel
et al. 2003; Taverna et al. 2005). Most of the observed lung
lesions were intravascular metastases representing tumor
cells that remain fully contained within a pulmonary vessel
without extravasations as shown by an H&E staining of
lung tissue (Fig. 6c). The percentage of mice with lung
micrometastases was found to be signiWcantly lower in
MMTV-c-neu;Tiam1¡/¡ mice compared to MMTV-c-
neu;Tiam1+/+ mice. We detected lung metastases in 50% of
the MMTV-c-neu;Tiam1+/+ mice and only in 18% of the
MMTV-c-neu;Tiam1¡/¡ mice (Fig. 6d). Tiam1 has been
shown to be involved in strengthening of E-cadherin-based
cell–cell adhesions, which inXuences metastatic capacities
of tumor cells (Malliri et al. 2004). However, E-cadherin
Fig. 4 Tiam1 does not aVect diVerentiation of mammary tumors in
MMTV-c-myc and MMTV-c-neu mice. a Sections of mammary tu-
mors from the indicated transgenic mice, stained with hematoxylin and
eosin (H&E). The scale bar indicates 100 m. b Immunohistochemi-
cal stainings of MMTV-c-myc and MMTV-c-neu tumors in Tiam+/+
and Tiam1¡/¡ mice. All tumors are positive for Keratin 8, which is spe-
ciWc for glandular characteristics. All tumors are negative for the epi-
dermal marker Keratin 1. Keratin 14 staining shows squamous
diVerentiation in MMTV-c-myc tumors, while MMTV-c-neu tumors































76 J Cancer Res Clin Oncol (2009) 135:69–80staining of MMTV-c-neu mammary tumors showed Welds
of E-cadherin-negative cells within a majority of E-cad-
herin-positive tumor cells in both Tiam1+/+ and Tiam1¡/¡
mice (Fig. 6e), suggesting that Tiam1-deWciency did not
aVect the metastatic capacity of Neu-induced mammary
tumors by aVecting the E-cadherin-mediated cell–cell adhe-
sions. Presumably, the lower incidence of metastases in the
Tiam1¡/¡ mice is a direct consequence of the lower number
of mammary tumors produced per mouse in Tiam1¡/¡
mice.
Discussion
We crossed Tiam1¡/¡ mice with MMTV-c-myc and
MMTV-c-neu transgenic mice to study the consequences of
Tiam1-deWciency in Myc-induced and Neu-induced mam-
mary tumorigenesis. Our analyses revealed that Tiam1 is
required for oncogenic signaling induced by Neu but not by
Myc. More speciWcally, we found that Tiam1-deWciency
delays the initiation of Neu-induced mammary tumors but
does not aVect the growth of these tumors. Initiation and
growth of Myc-induced mammary tumors was independent
of the expression of Tiam1.
Besides the dramatic delay in the onset of the Wrst detect-
able Neu-induced mammary tumors, also the total number
of tumors per mouse was lower in Tiam1¡/¡ mice than in
Tiam1+/+ animals. This is consistent with the Wndings in
skin and intestinal tumors, where the latency of tumor onset
and the number of tumors per mouse were dramatically
decreased in a Tiam1-deWcient background (Malliri et al.
2002b, 2006). In the skin tumor model, we found that
Tiam1¡/¡ mice produced less Ras-induced tumors, because
keratinocytes in the basal layer of the epidermis are more
susceptible to apoptosis (Malliri et al. 2002b). Recently, we
found that the Tiam1/Rac-mediated survival pathway in
keratinocytes acts through ROS-mediated activation of the
ERK pathway (Rygiel et al. 2008). Also in APC Min mice,
the decreased initiation of intestinal tumors by aberrant -
catenin signaling in Tiam1-deWcient mice compared to wild
type mice was attributed to increased apoptosis susceptibil-
ity (Malliri et al. 2006). Consistent with this, Tiam1 expres-
sion levels correlate with apoptosis susceptibility in human
colon tumor cells (Minard et al. 2006).
Fig. 5 Tiam1 aVects number of neu-induced mammary tumors. a
Western blot analyses. SDS lysates of snap frozen tumors isolated from
Tiam1+/+ and Tiam1¡/¡ MMTV-c-neu mice were blotted and probed
for detection of endogenous Tiam1 and transgenic Neu. The same blot
was probed for Rac1 and used as loading control. b Kinetics of the tu-
mor susceptibility in MMTV-neu;Tiam1§ mice (N = 20) is intermedi-
ate between MMTV-neu;Tiam1+/+ (N = 26) and MMTV-neu;Tiam1¡/¡
(N = 21) mice. The percentage of mice with a palpable mammary tumor
is presented in time. N is the number of mice analyzed. c Plot of the
total number of tumors with a size >4 mm per mouse in MMTV-c-
neu;Tiam1¡/¡, MMTV-c-neu;Tiam1§ and MMTV-c-neu;Tiam1+/+
mice at the time of necropsy. The median number of tumors per mouse
is indicated as a horizontal line and is 4 in Tiam1+/+ mice (N = 23;
range 1–15 tumors per mouse), 3 in Tiam1§ mice (N = 15; range 1–8
tumors per mouse) and only 2 in Tiam1¡/¡ mice (N = 17; range 1–7 tu-
mors per mouse). N is the number of mice analyzed. d Tumor growth
is similar in Tiam1+/+ and Tiam1¡/¡ mice. The average time for a tumor
to grow out from just palpable to a diameter that reached 10 mm in the
Tiam1¡/¡ mice (N = 14) compared to Tiam1¡/¡ mice (N = 23) is not
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J Cancer Res Clin Oncol (2009) 135:69–80 77It is likely that Tiam1-deWciency in the MMTV-c-neu
model aVects tumor initiation by increasing the susceptibil-
ity to apoptosis of the targeted mammary epithelial cells.
We have attempted to study apoptosis sensitivity in vivo,
but we could not Wnd signiWcant diVerences in apoptosis
between established Neu-induced tumors produced in
Tiam1+/+ and Tiam1¡/¡ mice (data not shown). Analysis of
apoptosis in tumor samples of MMTV-c-neu tumors by
TUNEL and Caspase 3 stainings appeared diYcult because
of the heterogeneity of these tumors. Moreover, apoptosis
resistance is most likely essential during the initiating
events of tumorigenicity, which is diYcult to study in vivo.
Once tumors have been formed, diVerences in apoptosis
sensitivity in Tiam1+/+ and Tiam1¡/¡ tumors are presum-
ably not detectable anymore, as Tiam1-independent events
have rescued the tumor-initiating cells from apoptosis. We
performed therefore in vitro studies using MDA-MB-361
breast cancer cells with high Neu expression and found that
the survival signaling of these tumor cells is dependent on
the presence of Tiam1. Similarly, as found in DMBA-
induced skin tumors and -catenin-induced intestinal
tumors, the presence of Tiam1 seems to be required to pre-
vent apoptosis during initiation of mammary tumors by the
Neu oncogene. Tiam1-mediated Rac-signaling might pre-
vent apoptosis by activating various well-known survival
signaling pathways including the NFkappaB and ERK
Fig. 6 a, b Apoptosis downstream of Neu signaling is Tiam1-depen-
dent. a Western blot analysis showing Tiam1 downregulation in
MDA–MB-361 breast cancer cells 3 days after transfection of Tiam1-
speciWc siRNA. As a control, a nonspeciWc scrambled siRNA sequence
was used. The same blot was probed with a Rac antibody and used as
a loading control. b Tiam1 downregulation increased apoptosis as
determined by the measurement of the amount of cytoplasmic histone-
associated DNA fragments. Apoptosis was measured 3 days after siR-
NA transfection. Bars show the average of three independent experi-
ments. c–e Metastasis of Neu-induced tumors was lower in Tiam¡/¡
than in Tiam+/+ mice. c Representative image of an H&E-stained slide
showing a typical nonextravasating metastatic embolus of mammary
adenocarcinoma cells in the lung of a MMTV-c-neu mice. The scale
bar indicates 100 m. d Mammary tumor-bearing Tiam1+/+ mice show
pulmonary metastases in 50% of the animals (N = 22), while metastatic
emboli in the lungs were found for only 18% of the Tiam¡/¡ mice
(N = 17). N is the number of mice analyzed. e E-cadherin expression in
mammary tumors in MMTV-c-neu;Tiam1+/+ and MMTV-c-

















































































78 J Cancer Res Clin Oncol (2009) 135:69–80pathways (Joneson and Bar-Sagi 1999; Rygiel et al. 2008;
Zahir et al. 2003).
Although less mammary tumors were produced in
Tiam1¡/¡ mice, the growth of the tumors in Tiam1+/+ and
Tiam1¡/¡ mice was the same once they were formed. In
contrast, we showed in skin and intestinal tumors a function
of Tiam1 in both initiation and growth of these tumors
(Malliri et al. 2002b, 2006). Interestingly, in DMBA (Ras)-
induced skin tumors, decreased growth of tumors in
Tiam1¡/¡ mice was found only when proliferation of
tumors was promoted by TPA treatment. Skin tumors that
were generated by treatment with DMBA only grew
equally well in the presence or absence of Tiam1 (Malliri
et al. 2002b), indicating that TPA-induced but not DMBA-
induced proliferation depends on Tiam1-mediated Rac acti-
vation. TPA is able to induce cyclin D1 expression, a regu-
lator of cell proliferation (Yan and Wenner 2001),
suggesting that Tiam1 is required for TPA-induced prolif-
eration by inXuencing cyclin D1 levels. Moreover, both the
Ras and Neu oncogenes are absolutely dependent on cyclin
D1 expression for mammary tumor formation in MMTV-
ras and MMTV-c-neu transgenic mice (Yu et al. 2001).
Cyclin D1-deWcient mice are resistant to Ras-induced and
Neu-induced mammary tumors, while they remain fully
sensitive to other oncogenic pathways (Yu et al. 2001).
However, the fact that the proliferation of Neu-induced
tumors is independent of Tiam1 suggests that Tiam1 does
not regulate cyclin D1 levels in mammary tumors. Indeed,
tumor lysates from MMTV-c-neu;Tiam1+/+ and MMTV-c-
neu;Tiam1¡/¡ mice revealed a large variation in cyclin D1
levels independent of the presence of Tiam1 (data not
shown). As Neu predominantly signals through Ras and the
growth of DMBA-only treated skin tumors is independent
of Tiam1, it is unlikely that Tiam1–Rac signaling contrib-
utes to Ras-controlled proliferation of tumors. Interestingly,
it has been shown that Neu-mediated protection from apop-
tosis is dependent on its association with the Par polarity
complex, while Neu-mediated proliferation is not (Aranda
et al. 2006). Tiam1 associates with the Par polarity com-
plex and is able to activate this complex (Mertens et al.
2006), providing a possible mechanism by which Tiam1
could interfere in initiation but not growth of Neu-induced
mammary tumors.
A higher number of metastases was found in the
MMTV-c-neu;Tiam1+/+ mice when compared to MMTV-c-
neu;Tiam1¡/¡ mice, suggesting that Tiam1 promotes
metastasis of breast tumors. Studies in human tumors also
show a positive correlation between Tiam1 expression and
progression and invasiveness of mammary, colon and pros-
tate tumors (Adam et al. 2001; Engers et al. 2006; Liu et al.
2007; Minard et al. 2005, 2006). This is in contrast to the
Wndings in skin and intestinal tumors, where progression
was associated with loss of Tiam1 (Malliri et al. 2002b,
2006). The latter could be explained by a function of Tiam1
in the formation and maintenance of intercellular adhesions
(Engers et al. 2001; Hordijk et al. 1997; Mertens et al.
2005; Uhlenbrock et al. 2004). In the MMTV-c-neu mice,
the metastases appear in pulmonary blood vessels as tight
tumor emboli that are thought to arise from circulating cell
clumps that get stocked in the veins of the lungs. As in
human inXammatory breast cancers (IBC), such circulating
tumor emboli might beneWt from strong E-cadherin-medi-
ated cell–cell interactions favoring passive dissemination in
distinct organs (Kleer et al. 2001; Tomlinson et al. 2001).
However, we could not Wnd signiWcant diVerences in E-
cadherin expression between Neu-induced tumors in
Tiam1+/+ and Tiam1¡/¡ mice that could support such a
mechanism. Alternatively, the higher number of metastases
found in the MMTV-c-neu;Tiam1+/+ mice could be the
result of the increased number of tumors found in these
mice.
In conclusion, the eVects of Tiam1-mediated Rac signal-
ing on tumorigenesis appear oncogene-dependent and
tumor cell type-dependent and either positively or nega-
tively correlate with tumor progression. As Tiam1-medi-
ated Rac activation controls diVerent signaling pathways
that may inXuence initiation, growth and progression of
tumors, the cellular outcome of altered Tiam1 expression
may depend on a balance between factors that promote or
inhibit the formation and progression of tumors.
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